Capricor Therapeutics (NASDAQ:CAPR) Earns Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR) in a research report report published on Thursday,Benzinga reports. HC Wainwright currently has a $77.00 target price on the biotechnology company’s stock.

CAPR has been the subject of several other research reports. Oppenheimer restated an “outperform” rating and issued a $15.00 price target on shares of Capricor Therapeutics in a research note on Monday, September 23rd. Cantor Fitzgerald boosted their price target on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. Maxim Group boosted their price target on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. Finally, Piper Sandler began coverage on shares of Capricor Therapeutics in a research note on Monday, October 21st. They issued an “overweight” rating and a $35.00 price target for the company. One analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Capricor Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $34.50.

Capricor Therapeutics Stock Performance

Capricor Therapeutics stock opened at $15.61 on Thursday. The firm has a 50 day moving average price of $16.70 and a 200 day moving average price of $10.89. The company has a market capitalization of $709.79 million, a PE ratio of -14.73 and a beta of 4.08. Capricor Therapeutics has a fifty-two week low of $3.52 and a fifty-two week high of $23.40.

Institutional Investors Weigh In On Capricor Therapeutics

Institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC lifted its position in shares of Capricor Therapeutics by 158.7% during the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock worth $656,000 after purchasing an additional 84,350 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Capricor Therapeutics during the 2nd quarter worth $426,000. State Street Corp lifted its position in shares of Capricor Therapeutics by 27.8% during the 3rd quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock worth $7,792,000 after purchasing an additional 111,291 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in Capricor Therapeutics in the third quarter valued at $3,806,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in Capricor Therapeutics in the third quarter valued at $161,000. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.